

Resource Summary Report

Generated by [PRECISE-TBI](#) on Aug 16, 2026

p53 (7F5) Rabbit mAb

RRID:AB_10695803

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2527, RRID:AB_10695803

Antibody Information

URL: http://antibodyregistry.org/AB_10695803

Proper Citation: Cell Signaling Technology Cat# 2527, RRID:AB_10695803

Target Antigen: p53 (7F5) Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IHC-P, IF-IC, F, ChIP. Consolidation on 10/2018: AB_10695803, AB_331211.

Antibody Name: p53 (7F5) Rabbit mAb

Description: This monoclonal targets p53 (7F5) Rabbit mAb

Target Organism: h, human, mk

Antibody ID: AB_10695803

Vendor: Cell Signaling Technology

Catalog Number: 2527

Record Creation Time: 20250820T045039+0000

Record Last Update: 20250820T200506+0000

Ratings and Alerts

No rating or validation information has been found for p53 (7F5) Rabbit mAb.

No alerts have been found for p53 (7F5) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 49 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Vaubel RA, et al. (2026) Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts. *Neuro-oncology advances*, 8(1), vda259.

O'Toole KT, et al. (2026) Identification and characterization of BRAF?TP53 interactions in melanoma. *Cell reports*, 45(4), 117078.

Wang X, et al. (2026) Regulation of lens epithelial cell senescence by cyclic mechanical stretch: Multi-omics insights into the mechanisms of lens aging. *Experimental eye research*, 270, 111089.

Liu CT, et al. (2026) Mutant Isocitrate Dehydrogenase 1 Sensitizes Intrahepatic Cholangiocarcinoma Cells to MDM2 Inhibitors. *Cancer research communications*, 6(3), 616.

Martinez-Martinez D, et al. (2025) Chemotherapy modulation by a cancer-associated microbiota metabolite. *Cell systems*, 16(9), 101397.

Wang M, et al. (2025) Gut microbiota protect against colorectal tumorigenesis through lncRNA Snhg9. *Developmental cell*.

Puzio-Kuter AM, et al. (2025) Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator. *Cancer discovery*, 15(6), 1159.

Huang Y, et al. (2025) Tumor suppressor protein p53 governs human trophoblast lineage development. *Cell reports*, 44(10), 116310.

Tzouanas CN, et al. (2025) Hepatic adaptation to chronic metabolic stress primes tumorigenesis. *Cell*.

Imaeda K, et al. (2025) LCN2-mediated ferroptosis resistance in tissue homeostasis and early-stage tumorigenesis of the fallopian tube epithelium. *iScience*, 28(6), 112654.

Lee SY, et al. (2025) A Novel Mechanism of the p53 Isoform ?40p53? in Regulating Collagen III Expression in TGF?1-Induced LX-2 Human Hepatic Stellate Cells. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 39(8), e70541.

Hockings H, et al. (2025) Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control. *Cancer research*, 85(18), 3503.

Vaubel RA, et al. (2025) Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-Wild-type Glioblastoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(17), 3771.

Wu M, et al. (2025) Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors. *Immunity*, 58(11), 2864.

Zampieri C, et al. (2025) The urokinase receptor/uPAR is a major effector of p53 gain-of-function mutations in gemcitabine-treated pancreatic ductal adenocarcinoma. *The Journal of biological chemistry*, 301(9), 110561.

Zhou L, et al. (2025) Mina53 catalyzes arginine demethylation of p53 to promote tumor growth. *Cell reports*, 44(2), 115242.

Ogawa A, et al. (2025) SLFN11-mediated ribosome biogenesis impairment induces TP53-independent apoptosis. *Molecular cell*, 85(5), 894.

Um JH, et al. (2025) Genomic and Single-Cell Analyses Characterize Patient-Derived Tumor Organoids to Enable Personalized Therapy for Head and Neck Squamous Cell Carcinoma. *Cancer research*, 85(14), 2726.

Fukuda K, et al. (2024) Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations. *Cell reports. Medicine*, 5(6), 101578.

Guerrero Zuniga A, et al. (2024) Sustained ERK signaling promotes G2 cell cycle exit and primes cells for whole-genome duplication. *Developmental cell*, 59(13), 1724.